STI Stock Trade Intelligence
NXN

Nexsen Ltd

Health Care · ASX:NXN
$0.1350
▼ -3.57%
Market cap
$13M
Turnover
$16,046
Last price
$0.1350
Day change
-3.57%
Announcements
13
Range, past year
Open 0.255 · Low 0.105 · Now 0.135 · High 0.345
Open NXN in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

NXN momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-10-13.
Momentum quality
39/100
Wyckoff phase
Accumulation4d
Trend stage
Neutral
1 Day
-3.6%
1 Week
+0.0%
1 Month
-25.0%
RSI
37
Avg daily range
13.5%

Nexsen Ltd scores 39 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 4 trading days. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.

Against the wider market it is currently underperforming and the institutional accumulation signal reads low.

What stands out
  • Trend R² 0.93 — highly linear uptrend
  • Volume 1.6× 60-day avg
Points to watch
  • 60d drawdown -61.0%
  • High volatility (ATR 13.5%)
  • Thin liquidity
  • Risk rating: Very High
  • Composite downside risk elevated
NXN appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

NXN announcements

Recent price-sensitive releases.
  • 2026-09-25 Proposed FlashDx joint venture builds on CE-marked GBS test Progress Report
  • 2026-09-25 Reinstatement to Quotation Reinstatement to Official Quotation
  • 2026-09-24 Suspension from Quotation Suspension from Official Quotation
  • 2026-09-24 Clear pathway defined to optimise StrepSure Progress Report
  • 2026-09-22 Trading Halt Trading Halt
  • 2026-08-31 Annual Report - FY 2026 Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-07-29 Quarterly Report - Q4 FY26 Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.